UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

February 26, 2019

Date of report (Date of earliest event reported)

IMAX Corporation

(Exact Name of Registrant as Specified in Its Charter)

Canada

(State or Other Jurisdiction of Incorporation)

1-35066 (Commission File Number) 98-0140269 (I.R.S. Employer Identification Number)

2525 Speakman Drive Mississauga, Ontario, Canada L5K 1B1 (905) 403-6500 902 Broadway, Floor 20 New York, New York, USA 10010 (212) 821-0100

(Address of principal executive offices, zip code, telephone numbers)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On February 26, 2019, IMAX Corporation (the "Company") issued a press release announcing the Company's financial and operating results for the quarter and twelve months ended December 31, 2018, a copy of which is attached as Exhibit 99.1.

The information in this current report on Form 8-K, including the Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | Description |
|-------------|--|
| 99.1 | Press Release dated February 26, 2019. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMAX Corporation

(Registrant)

By:/s/ Richard L. GelfondName:Richard L. GelfondTitle:Chief Executive Officer & Director

3

Date: February 26, 2019

Exhibit 99.1



IMAX CORPORATION REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

HIGHLIGHTS

- Delivered full-year 2018 GAAP net income per share of \$0.36, compared to GAAP net income per share of \$0.04, in 2017.
- 2018 adjusted net income per share was \$0.91, compared to \$0.62 in 2017, an increase of 46.8%.
- Strong box office and continued cost discipline drove a 381-basis point increase in 2018 operating income margin, compared to 2017.
- IMAX surpassed \$1 billion in global box office for the first time in its history and delivered its highest-grossing year in China.
- Year-to-date in 2019, IMAX box office in China reached \$78 million, up 61%, compared to last year.

NEW YORK – Feb. 26, 2019 – IMAX Corporation (NYSE:IMAX) today reported fourth quarter 2018 revenues of \$109.0 million, gross profit of \$54.6 million and net income attributable to common shareholders of \$1.7 million, or \$0.03 per diluted share. Adjusted net income attributable to common shareholders for the fourth quarter was \$16.4 million, or \$0.26 per diluted share. Adjusted EBITDA was \$36.4 million. For reconciliations of reported results to non-GAAP financial results, and for the definition and reconciliation of Adjusted EBITDA, please see the end of this press release.

The Company also reported full year 2018 revenues of \$374.4 million, gross profit of \$207.9 million and net income attributable to common shareholders of \$22.8 million, or \$0.36 per diluted share. Adjusted net income attributable to common shareholders for the year ended December 31, 2018 was \$57.8 million, or \$0.91 per diluted share. Adjusted EBITDA was \$133.2 million.

"We believe our achievements last year set the stage for IMAX to have a blockbuster year in 2019. We further differentiated The IMAX Experience[®], increased awareness of the IMAX brand and tackled key challenges in China, where we delivered our strongest box office year ever and doubled the industry growth rate," said IMAX CEO Richard L. Gelfond. "While these achievements have already begun paying dividends—as evidenced by the 47% year-over-year increase in adjusted earnings per share—we anticipate these initiatives to continue to improve the performance of our business in 2019 and beyond. And we have hit the ground running in 2019. Year-to-to date, we have already achieved \$78 million of box office in China, a 61% increase compared to 2018. Overall, we are encouraged by our recent results as we head into the blockbuster filled calendar, which includes highly anticipated films such as *Captain Marvel, Avengers: Endgame, The Lion King* and *Star Wars Episode IX.*"

Fourth Quarter 2018 Results

Network Update

During the quarter, the Company installed 88 theater systems, 67 of which were for new theater locations. The total IMAX[®] theater network consisted of 1,505 systems as of December 31, 2018, of which 1,409 were in commercial multiplexes. There were 564 theaters in backlog as of December 31, 2018, compared to the 499 in backlog as of December 31, 2017.

IMAX also signed contracts for 12 new theaters and 2 upgrades in the fourth quarter. During 2018, the Company signed agreements for 203 IMAX with Laser systems, 59 of which were new systems, 114 of which were upgrades to existing IMAX theaters and 30 of which were amendments to existing backlog arrangements. For a breakdown of theater system signings, installations, network and backlog by type for the fourth quarter, please see the end of this press release.

"The story is quite simple. Beginning in 2017 we made a series of strategic decisions to turn around our business," said Gelfond. "From top to bottom, the evidence is clear in 2018 that these initiatives are working as our growth, margin and



return metrics are on solidly positive trend lines. We have confidence each of these trends will continue in 2019 and our margin and return improvement should accelerate as we continue to execute against the initiatives we laid out."

Box Office Update

Gross box office from IMAX DMR[®] films was \$236.7 million in the fourth quarter of 2018 compared to \$278.1 million in the fourth quarter of 2017, primarily due to a stronger film slate in the fourth quarter of 2017 which included *Star Wars: The Last Jedi*. Gross box office was generated primarily by the exhibition of 29 films (22 new and 7 carryover), as compared to 26 films (22 new and 4 carryover) exhibited in the fourth quarter of 2017.

Fourth-Quarter Consolidated Results

The gross margin across all segments in the fourth quarter of 2018 was \$54.6 million, or 50.1% of total revenues, compared to \$60.1 million, or 47.9% of total revenues, in the fourth quarter of 2017. Operating expenses (which includes SG&A, excluding stock-based compensation, plus R&D) were \$28.0 million in the quarter, compared to \$27.2 million in 2017.

Fourth-Quarter Segment Results

Network Business

- Network business revenues were \$41.7 million in the quarter, compared with \$53.8 million in the prior-year period. Gross margin for the network business was 59.2% in the most recent quarter, compared to 64.3% in the prior-year period.
- IMAX DMR revenues were \$25.2 million in the fourth quarter of 2018, compared to \$31.7 million in the fourth quarter of 2017. Gross margin for the IMAX DMR segment was 60.5%, compared to 60.6% in the prior-year comparative period.
- Revenues from joint revenue-sharing arrangements were \$16.5 million in the quarter, compared with \$20.7 million in the prior-year period. Gross margin for joint revenue-sharing arrangements was 57.2%, compared to 67.8% in the prior-year comparative period.

Theater Business

- Theater business segment revenues were \$61.9 million in the quarter, compared with \$55.5 million in the prior-year period, primarily reflecting the variable consideration being recognized due to the adoption of ASC Topic 606, as well as 2 additional installations of sales-type theaters.
- Gross margin on sales and sales-type leases was 51.0% compared with 61.4% in the year-ago period. The decline was driven by the mix of theater installations (new vs. upgrades) compared to the prior year, which can vary each year.

In addition to the Company's core revenue segments, new business revenues were \$0.8 million in the quarter, compared to \$13.0 million in the same period last year. New business revenues in 2017 were driven primarily by the launch of *Marvel's Inhumans*. The company recognized a gross loss of \$0.5 million in the quarter, compared to a gross loss of \$2.7 million in the fourth quarter of 2017.

Supplemental Materials

For more information about the Company's results, please refer to the IMAX Investor Relations website located at investors.imax.com.

Investor Relations Website and Social Media

On a weekly basis, the Company posts quarter-to-date box office results on the IMAX Investor Relations website located at www.imax.com/content/investor-relations. The Company expects to provide such updates on Friday of each week, although the Company may change this timing without notice. Results will be displayed with a one-week lag. In addition, the Company maintains a Twitter account: @IMAX_Investors. The Company intends to use Twitter to disclose the box office information, as well as other information that may be of interest to the Company's investor community.

The information posted on the Company's website and/or via its Twitter account may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its Twitter account in addition to the Company's press releases, SEC filings and public conference calls and webcasts.

Conference Call

The Company will host a conference call today at 4:30PM ET to discuss its fourth quarter and full year 2018 financial results. This call is being webcast by Nasdaq and can be accessed at investors.imax.com. To access the call via telephone, interested parties in the US and Canada should dial (800) 667-5617 approximately 5 to 10 minutes before the call begins. Other international callers should dial (647) 490-5367. The conference ID for the call is 7993555. A replay of the call will be available via webcast at investors.imax.com or via telephone by dialing (888) 203-1112 (US and Canada), or (647) 436-0148 (international). The Conference ID for the telephone replay is 7993555.

About IMAX Corporation

IMAX, an innovator in entertainment technology, combines proprietary software, architecture and equipment to create experiences that take you beyond the edge of your seat to a world you've never imagined. Top filmmakers and studios are utilizing IMAX theaters to connect with audiences in extraordinary ways, and, as such, IMAX's network is among the most important and successful theatrical distribution platforms for major event films around the globe.

IMAX is headquartered in New York, Toronto and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of December 31, 2018, there were 1,505 IMAX theater systems (1,409 commercial multiplexes, 14 commercial destinations, 82 institutional) operating in 80 countries. On Oct. 8, 2015, shares of IMAX China, a subsidiary of IMAX Corp., began trading on the Hong Kong Stock Exchange under the stock code "HK.1970."

IMAX[®], IMAX[®] 3D, IMAX DMR[®], Experience It In IMAX[®], An IMAX 3D Experience[®], The IMAX Experience[®], IMAX Is Believing[®] and IMAX nXos[®] are trademarks of IMAX Corporation. More information about the Company can be found at www.imax.com. You may also connect with IMAX on Facebook (www.facebook.com/imax), Twitter (www.twitter.com/imax) and YouTube (www.youtube.com/imaxmovies).

###

This press release contains forward looking statements that are based on IMAX management's assumptions and existing information and involve certain risks and uncertainties which could cause actual results to differ materially from future results expressed or implied by such forward looking statements. Important factors that could affect these statements include, but are not limited to, references to future capital expenditures (including the amount and nature thereof), business and technology strategies and measures to implement strategies, competitive strengths, goals, expansion and growth of business, operations and technology, plans and references to the future success of IMAX Corporation together with its consolidated subsidiaries (the "Company") and expectations regarding the Company's future operating, financial and technological results. These forward-looking statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the expectations and predictions of the Company is subject to a number of risks and uncertainties, including, but not limited to, risks associated with investments and operations in foreign jurisdictions and any future international expansion, including those related to economic, political and regulatory policies of local governments and laws and policies of the United States and Canada; risks related to the Company's growth and operations in China; the performance of IMAX DMR films; the signing of theater system agreements; conditions, changes and developments in the commercial exhibition industry; risks related to currency fluctuations; the potential impact of increased competition in the markets within which the Company operates; competitive actions by other companies; the failure to respond to change and advancements in digital technology; risks relating to recent consolidation among commercial exhibitors and studios; risks related to new business initiatives; conditions in the in-home and out-of-home entertainment industries; the opportunities (or lack thereof) that may be presented to and pursued by the Company; risks related to cyber-security and data privacy; risks related to the Company's inability to protect the Company's intellectual property; general economic, market or business conditions; the failure to convert theater system backlog into revenue; changes in laws or regulations; the failure to fully realize the projected cost savings and benefits from any of the Company's restructuring initiatives; and other factors, many of which are beyond the control of the Company. These factors, other risks and uncertainties and financial details are discussed in IMAX's most recent Annual Report on Form 10-K and

Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update publicly or otherwise revise any forward looking statements, whether as a result of new information, future events or otherwise.

For additional information please contact:

Investors: IMAX Corporation, New York Michael K. Mougias 212-821-0187 mmougias@imax.com *Media:* IMAX Corporation, New York Amanda Collins 212-821-0155 abcollins@imax.com

Additional Information

Signings and Installations

December 31, 2018

| | Year Ended De 2018 | <u>ecember 31,</u> 2017 |
|--|--|---|
| Theater Signings: | 2010 | 2017 |
| Full new sales and sales-type lease arrangements | 57 | 85 |
| New traditional joint revenue sharing lease arrangements | 55 | 35 |
| New hybrid joint revenue sharing lease arrangements | 10 | 50 |
| Total new theaters | 122 | 170 |
| Upgrades of IMAX theater systems | 112(1) | 7 |
| Total Theater Signings | 234 | 177 |
| Total Theater Signings | | |
| | Year Ended De | combor 21 |
| | 2018 | 2017 |
| Theater Installations: | | |
| Full new sales and sales-type lease arrangements | 63 | 60 |
| New traditional joint revenue sharing lease arrangements | 72 | 86 |
| New hybrid joint revenue sharing lease arrangements | 14 | 19 |
| Total new theaters | 149 | 165 |
| Upgrades of IMAX theater systems | 23 | 5 |
| Total Theater Installations | 172 | 170 |
| | | |
| | | |
| | As of Decer | nber 31, |
| | As of Decer 2018 | nber 31, |
| Theater Backlog: | 2018 | 2017 |
| Sales and sales-type lease arrangements | | · · · · · · · · · · · · · · · · · · · |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements | <u>2018</u> 177 (2) | <u>2017</u> 162 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements | <u>2018</u> 177 (2) 118 | <u>2017</u> 162 121 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements | 2018 177 (2) 118 269 (3) | <u>2017</u> 162 121 216 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements | <u>2018</u> 177 (2) 118 | <u>2017</u> 162 121 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements | 2018 177 (2) 118 269 (3) 564 (4) | 2017 162 121 216 499(5) |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements | 2018 177 (2) 118 269 (3) 564 (4) As of Decer | 2017 162 121 216 499(5) nber 31, |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog | 2018 177 (2) 118 269 (3) 564 (4) | 2017 162 121 216 499(5) |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: | 2018 177 (2) 118 269 (3) 564 (4) As of Decer | 2017 162 121 216 499(5) nber 31, |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: | 2018 177 (2) 118 269 (3) 564 (4) As of Decer 2018 | 2017 162 121 216 499(5) nber 31, 2017 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements | 2018 177 (2) 118 269 (3) 564 (4) As of Decer 2018 611 | 2017 162 121 216 499(5) nber 31, 2017 525 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements Traditional joint revenue sharing arrangements | 2018 177 (2) 118 269 (3) 564 (4) As of Decer 2018 611 674 | 2017 162 121 216 499(5) mber 31, 2017 525 613 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements Traditional joint revenue sharing arrangements Hybrid joint revenue sharing lease arrangements | 2018 177 (2) 118 269 (3) 564 (4) <u>As of Decer</u> 2018 611 674 124 | 2017 162 121 216 499(5) mber 31, 2017 525 613 134 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements Traditional joint revenue sharing arrangements Hybrid joint revenue sharing lease arrangements Total Commercial Multiplex Theaters: | 2018 177 (2) 118 269 (3) 564 (4) <u>As of Decer</u> 2018 611 674 124 1,409 | 2017 162 121 216 499(5) mber 31, 2017 525 613 134 1,272 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements Traditional joint revenue sharing arrangements Hybrid joint revenue sharing lease arrangements | 2018 177 (2) 118 269 (3) 564 (4) <u>As of Decer</u> 2018 611 674 124 | 2017 162 121 216 499(5) mber 31, 2017 525 613 134 |
| Sales and sales-type lease arrangements Joint revenue sharing arrangements Hybrid lease arrangements Traditional arrangements Total Theater Backlog Theater Network: Commercial Multiplex Theaters: Sales and sales-type lease arrangements Traditional joint revenue sharing arrangements Hybrid joint revenue sharing lease arrangements Total Commercial Multiplex Theaters Commercial Multiplex Theaters Commercial Multiplex Theaters Commercial Multiplex Theaters | 2018 177 (2) 118 269 (3) 564 (4) <u>As of Decer</u> 2018 611 674 124 1,409 14 | 2017 162 121 216 499(5) mber 31, 2017 525 613 134 1,272 12 |

(1) Includes 105 theater systems related to existing AMC, Regal and Pathé theaters to be upgraded to IMAX with Laser projection systems on new lease terms ranging from 10 to 12 years.

(2) Includes 20 hybrid sales theater systems which were previously classified under joint revenue sharing arrangements – hybrid sales arrangements.

(3) Includes 46 theater systems where the customer has the option to convert from a joint revenue sharing arrangement to a sales arrangement.

(4) Includes 83 new laser projection system configurations (73 of the 83 new systems are IMAX with Laser projection system configurations) and 100 upgrades of existing locations to laser projection system configurations (98 of the 100 upgrades are for the IMAX with Laser projection system configurations).

(5) Includes 27 new laser projection system configurations (three of the 27 new systems are IMAX with Laser projection system configurations) and five upgrades of existing locations to laser projection system configurations (three of the five upgrades are for the IMAX with Laser projection system configurations).

IMAX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars, except per share amounts)

| | Three Months Ended December 31, 2018 2017 | | Years End Decem | ber 31, |
|---|---|-----------|--------------------|-----------|
| Revenues | 2018 | 2017 | 2018 | 2017 |
| Equipment and product sales | \$ 46,409 | \$ 39,701 | \$106,591 | \$103,294 |
| Services | 42,769 | 62,330 | 181,740 | 195,594 |
| Rentals | 16,667 | 21,138 | 74,472 | 72,281 |
| Finance income | 3,119 | 2,384 | 11,598 | 9,598 |
| | 108,964 | 125,553 | 374,401 | 380,767 |
| Costs and expenses applicable to revenues | | | | |
| Equipment and product sales | 25,233 | 15,820 | 54,853 | 48,172 |
| Services | 21,428 | 40,951 | 84,236 | 120,629 |
| Rentals | 7,661 | 8,634 | 27,383 | 26,720 |
| | 54,322 | 65,405 | 166,472 | 195,521 |
| Gross margin | 54,642 | 60,148 | 207,929 | 185,246 |
| Selling, general and administrative expenses | 30,380 | 25,199 | 117,477 | 109,882 |
| Research and development | 2,186 | 6,217 | 13,728 | 20,855 |
| Amortization of intangibles | 1,249 | 837 | 4,145 | 3,019 |
| Receivable provisions, net of recoveries | 1,463 | 559 | 3,130 | 2,647 |
| Asset impairments | | — | — | 1,225 |
| Legal arbitration award | 4,237 | | 11,737 | — |
| Executive transition costs | 2,994 | | 2,994 | — |
| Exit costs, restructuring charges and associated impairments | 8,384 | 2,479 | 9,542 | 16,174 |
| Income from operations | 3,749 | 24,857 | 45,176 | 31,444 |
| Retirement benefits non-service expense | (125) | (130) | (499) | (518) |
| Interest income | 723 | 266 | 1,844 | 1,027 |
| Interest expense | (613) | (524) | (2,916) | (1,942) |
| Income from operations before income taxes | 3,734 | 24,469 | 43,605 | 30,011 |
| Provision for income taxes | 22 | (15,905) | (9,518) | (16,790) |
| Gain (loss) from equity-accounted investments, net of tax | 15 | 134 | (492) | (703) |
| Net income | 3,771 | 8,698 | 33,595 | 12,518 |
| Less: net income attributable to non-controlling interests | (2,077) | (3,867) | (10,751) | (10,174) |
| Net income attributable to common shareholders | \$ 1,694 | \$ 4,831 | \$ 22,844 | \$ 2,344 |
| Net income per share attributable to common shareholders—basic and diluted: | | | | |
| Net income per share—basic | \$ 0.03 | \$ 0.08 | \$ 0.36 | \$ 0.04 |
| Net income per share—diluted | \$ 0.03 | \$ 0.08 | \$ 0.36 | \$ 0.04 |
| Weighted average number of shares outstanding (000's): | | | | |
| Basic | 61,924 | 64,658 | 63,075 | 65,380 |
| Fully Diluted | 62,127 | 64,790 | 63,207 | 65,540 |
| Additional Disclosure: | | | | |
| Depreciation and amortization(1) | \$ 15,453 | \$ 27,040 | \$ 57,437 | \$ 66,807 |

(1) Includes \$0.1 million and \$1.1 million of amortization of deferred financing costs charged to interest expense for the three months and year ended December 31, 2018 (2017—\$0.2 million and \$0.6 million, respectively).

IMAX CORPORATION CONSOLIDATED BALANCE SHEETS In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars)

| | As at Dece 2018 | ember 31, 2017 |
|---|--------------------|-------------------|
| Assets | | |
| Cash and cash equivalents | \$141,590 | \$158,725 |
| Accounts receivable, net of allowance for doubtful accounts of \$3,174 (December 31, 2017 — \$1,613) | 93,309 | 130,546 |
| Financing receivables, net of allowance for uncollectible amounts | 127,432 | 129,494 |
| Inventories | 44,560 | 30,788 |
| Prepaid expenses | 10,294 | 7,549 |
| Film assets | 16,367 | 5,026 |
| Property, plant and equipment | 280,658 | 276,781 |
| Other assets | 55,004 | 26,757 |
| Deferred income taxes | 31,264 | 30,708 |
| Other intangible assets | 34,095 | 31,211 |
| Goodwill | 39,027 | 39,027 |
| Total assets | \$873,600 | \$866,612 |
| Liabilities | | |
| Bank indebtedness | \$ 37,753 | \$ 25,357 |
| Accounts payable | 32,057 | 24,235 |
| Accrued and other liabilities | 97,724 | 100,140 |
| Deferred revenue | 106,709 | 113,270 |
| Total liabilities | 274,243 | 263,002 |
| Commitments and contingencies | | |
| Non-controlling interests | 6,439 | 1,353 |
| Shareholders' equity | | |
| Capital stock common shares — no par value. Authorized — unlimited number. 61,478,168 — issued and 61,433,589 — | | |
| outstanding (December 31, 2017 — 64,902,201 — issued and 64,695,550 — outstanding) | 422,455 | 445,797 |
| Less: Treasury stock, 44,579 shares at cost (December 31, 2017 — 206,651) | (916) | (5,133) |
| Other equity | 179,595 | 175,300 |
| Accumulated deficit | (85,385) | (87,592) |
| Accumulated other comprehensive loss | (3,588) | (626) |
| Total shareholders' equity attributable to common shareholders | 512,161 | 527,746 |
| Non-controlling interests | 80,757 | 74,511 |
| Total shareholders' equity | 592,918 | 602,257 |
| Total liabilities and shareholders' equity | \$ 873,600 | \$ 866,612 |

IMAX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars)

| Cash provided by (used in): | | Years Ended | |
|---|--|-------------|------------|
| Operating Activities \$ 33.59 \$ 12.518 Net income \$ 33.59 \$ 12.518 Adjustments to reconcile net income to cash from operations: - - Depreciation and amortization 57.437 66.807 Write-downs, net of recoveries 11.770 29.568 Change in deferred income taxes 66.923 24.075 Unrealized foreign currency exchange loss (gain) 23 24.075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investees 397 397 Investment in film assets (23,200) (34.645) Change in other non-cash operating assets and liabilities 199.72 85.366 Investing Activities 199.72 85.366 Investing Activities - (1.606) Acquisition of oher intangible assets (6.896) (5.214) Net cash used in investing activities - - Increase in Bank indebtedness (50.667) (2.000) Requintase of common shares (50.667) (2.000) Requintase of innvesting activitie | Cash provided by (used in): | 2018 | 2017 |
| Net income \$ 33,595 \$ 12,518 Adjustments to reconcile net income to cash from operations: 57,437 66,807 Write-downs, net of recoveries 11,770 29,558 Change in deferred income taxes (6,923) (4,017) Stock and other non-cash compensation 23,723 24,075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investments 95 306 Gain on non-cash contribution to equity-accounted investmees 397 397 Investment in film assets (23,200) (34,645) Changes in other non-cash operating assets and liabilities 12,447 (9,141) Net cash provided by operating quipment (13,368) (24,143) Investing Activities (24,143) (42,634) Investment in joint revenue sharing equipment (13,669) (5,214) Net cash used in investing activities (6,697) (73,597) Financing Activities (50,667) (70,602) (72,309) Repartment of bank indebtedness (50,067) (2,000) Reparkent of common shares, IMAX China (60,684) (1,606) | | | |
| Adjustments to reconcile net income to cash from operations: 57,437 66,807 Depreciation and amortization 57,437 66,807 Write-downs, net of recoveries 11,770 29,568 Change in deferred income taxes (6,923) (4,017) Stock and other non-cash compensation 23,723 24,075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investments 95 306 Gain on no-cash compensation (23,200) (34,645) Changes in other non-cash operating assets and liabilities 109,972 85,366 Investment in film assets (24,143) (42,634) Investing Activities 109,972 85,366 Investing Activities - (1,606) Acquisition of other intangible assets (8,699) (5,214) Net cash used in investing activities - (1,606) Reparament of bank indebredness (50,667) (2,000) Reparament of bank indebredness (50,667) (2,000) Reparament of bank indebredness (50,667) (2,000) Reparament of mark indebredness (50,667) (2,00 | | \$ 32.505 | ¢ 17519 |
| Depreciation and amortization57,43766,807Write-downs, net of recoveries11,77029,568Change in deferred income taxes(6,6)233(4,017)Stock and other non-cash compensation23,72324,075Unrealized foreign currency exchange loss (gain)631(502)Loss from equity-accounted investments95306Gain on non-cash contribution to equity-accounted investees397397Investment in film assets(23,200)(34,645)Changes in other non-cash operating assets and liabilities12,447(9,141)Net cash provided by operating activities109,97285,366Purchase of property, plant and equipment(13,368)(24,143)Investing Activities(34,810)(42,634)Purchase of property, plant and equipment(34,810)(42,634)Investing Activities(6,696)(5,214)Net cash used in investing activities(6,696)(5,214)Net cash used in investing activities(56,697)(2,000)Repurchase of common shares(71,479)(46,140)Repurchase of common shares(71,479)(46,140)Repurchase of common shares(71,479)(46,140)Repurchase of common shares issued—stock options exercised(1,437)(6000)Increase in bank indebtedness(5,249)(5,234)(5,234)Changes in subact of the further settlement of restricted share units(5,249)(5,234)Increase in bank indebtedness(5,249)(5,234)(5,234)Increa | | ψ 55,555 | ψ 12,510 |
| Write-downs, net of recoveries 11,770 29,568 Change in deferred income taxes (6,923) (4,017) Stock and other non-cash compensation 23,723 22,4075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investments 95 306 Gain on non-cash contribution to equity-accounted investees 397 397 Investment in film assets (23,200) (34,645) Changes in other non-cash contribution to equity-accounted investees 12,447 (9,141) Net cash provided by operating activities 109,972 85,366 Investing Activities 11,770 (13,368) (24,143) Investment in joint revenue sharing equipment (34,461) (42,634) Investment in new business ventures - (1,069) (5,214) Investment in new business ventures (6,6874) (73,597) Financing Activities (5,607) - - Increase in bank indebtedness (5,000) - - Repayment of bank indebtedness (5,000) - - - Settlement of restrict share units and options < | | 57 /37 | 66 807 |
| Change in deferred income taxes (6,923) (4,017) Stock and other non-cash compensation 23,723 24,075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investments 95 306 Gain on non-cash contribution to equity-accounted investees 397 397 Investment in film assets (23,200) (34,645) Changes in other non-cash operating assets and liabilities 12,447 (9,141) Net cash provided by operating activities 109,972 85,366 Investiment in joint revenue sharing equipment (34,810) (42,634) Investment in point revenue sharing equipment (34,810) (42,634) Investment in new business ventures — (1,606) Acquisition of other intargible assets (8,696) (5,214) Net cash used in investing activities 55,000 — Increase in bank indebtedness (50,067) (2,000) Repurchase of common shares (50,667) (2,000) Repurchase of common shares, IMAX China (6,084) — Repurchase of common shares issued—stock options exercised 1,017 16,6684 <t< td=""><td></td><td></td><td>,</td></t<> | | | , |
| Stock and other non-cash compensation 23,723 24,075 Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investents 95 306 Gain on non-cash contribution to equity-accounted investees 397 397 Investment in film assets (23,200) (34,645) Changes in other non-cash operating assets and liabilities 12,447 (9,141) Net cash provided by operating activities 109,972 85,366 Investing Activities 109,972 85,366 Investing Activities - (1,606) Acquisition of other intragible assets (8,696) (5,214) Net cash used in investing activities 65,000 - Increase in bank indebtedness 65,000 - Repayment of bank indebtedness (50,667) (2,000) Repayment of bank indebtedness (50,667) (2,000) Repayment of bank indebtedness (50,667) (2,000) Repayment of bank indebtedness (50,667) (2,001) Repayment of bank indebtedness (50,667) (2,003) <tr< td=""><td></td><td></td><td></td></tr<> | | | |
| Unrealized foreign currency exchange loss (gain) 631 (502) Loss from equity-accounted investments 95 306 Gain on non-cash contribution to equity-accounted investees 397 397 Investment in film assets (23,200) (34,645) Changes in other non-cash operating assets and liabilities 12,447 (9,141) Net cash provided by operating activities 109,972 85,366 Investing Activities 109,972 85,366 Investing Activities (13,368) (24,143) Investment in joint revenue sharing equipment (13,368) (24,143) Investment in new business ventures - (1,606) Acquisition of other intangible assets (6,6364) (73,597) Financing Activities (50,667) (2,000) Repayment of bank indebtedness 65,000 - Repayment of bank indebtedness (50,667) (2,003) Repurchase of common shares (71,479) (46,140) Common shares issued—stock options exercised (1,017) (6600) Repurchase of common shares induction of restricted share units (5,249) (5,133) Thoreas uitheld and paid | | | |
| Loss from equity-accounted investments95306Gain on non-cash contribution to equity-accounted investees397397Investment in film assets(23,200)(34,645)Changes in other non-cash operating assets and liabilities12,447(9,141)Net cash provided by operating activities109,97285,366Investment in joint revenue sharing equipment(13,368)(24,143)Investment in joint revenue sharing equipment(34,810)(42,634)Investment in new business ventures | | | |
| Gain on non-cash contribution to equity-accounted investees397397Investment in film assets(23,200)(34,645)Changes in other non-cash operating assets and liabilities12,447(9,141)Net cash provided by operating activities109,97288,366Investing Activities103,268)(24,143)Purchase of property, plant and equipment(13,368)(24,143)Investment in joint revenue sharing equipment(34,810)(42,634)Investment in in othe trutangible assets(6,699)(5,214)Acquisition of other intangible assets(56,874)(73,597)Financing Activities(56,6874)(73,597)Pincrease in bank indebtedness(50,067)(2,000)Repayment of bank indebtedness(50,667)(2,000)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Comano shares issued—stock options exercised(1,437)(600)Issues of subsidiary shares to non-controlling interests(5,249)(5,133)Taxes withheld and paid on employee stock avards vested(1,437)(600)Issue of subsidiary shares to non-controlling interests(5,034)—Credit facility amendment fees paid(1,934)—Net cash used in financing activities(5,249)(5,133)Dividends paid to non-controlling interests(6,934)—Credit facility amendment fees paid(1,935)(46,034)Credit facility amendment fees paid(1,935) <td< td=""><td></td><td></td><td></td></td<> | | | |
| Investment in film assets(23,200)(34,645)Changes in other non-cash operating assets and liabilities12,447(9,141)Net cash provided by operating activities109,97285,366Investing Activities(13,368)(24,143)Investment in joint revenue sharing equipment(13,368)(24,143)Investment in of other intangible assets(34,810)(42,634)Net cash used in investing activities(56,8674)(73,597)Financing Activities(56,667)(2,000)Repayment of bank indebtedness(50,667)(2,000)Repayment of bank indebtedness(50,667)(20,000)Repurchase of common shares, IMAX China(6,084)Settlement of restricted share units and options(11,437)(600)Issair sisued—stock option exercised10,1716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issued of subidiary shares to non-controlling interests(6,934)Credit facility amendment fees paid(1,909)Net cash used in financing activities(57,536)Effects of exchange rate changes on cash(60,034)Credit facility amendment fees paid(1,909)Net cash used in financing activities(57,536)(267)Dividends paid to non-controlling interests(57,536)(267)Credit facility amendment fees paid(15,034)- | | | |
| Changes in other non-cash operating assets and liabilities12,447(9,141)Net cash provided by operating activities109,97285,366Investing Activities(13,368)(24,143)Purchase of property, plant and equipment(34,810)(42,634)Investment in joint revenue sharing equipment(34,810)(42,634)Investment in new business ventures—(1,606)Acquisition of other intangible assets(8,696)(5,214)Net cash used in investing activities—(1,606)Financing Activities—(1,606)Increase in bank indebtedness(50,667)(2,000)Repartnet of bank indebtedness(50,667)(2,000)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796—Dividends paid to non-controlling interests(7,356)—Credit facility amendment fees paid(1,909)—Net cash used in financing activities(6,536)—Effects of exchanger ate changes on cash(627)(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents during year(17,135)(46 | Investment in film assets | | |
| Net cash provided by operating activities 109,972 85,366 Investing Activities (13,368) (24,143) Purchase of property, plant and equipment (34,810) (42,634) Investment in joint revenue sharing equipment (34,810) (42,634) Investment in new business ventures - (1,606) Acquisition of other intangible assets (8,696) (5,214) Net cash used in investing activities (56,874) (73,597) Financing Activities - - Increase in bank indebtedness (50,067) (2,000) Repayment of bank indebtedness (50,667) (2,000) Repurchase of common shares, IMAX China (6,084) - Settlement of restricted share units and options (916) (20,331) Common shares issued—stock options exercised 1,017 16,668 Treasury stock repurchased for future settlement of restricted share units (5,249) (5,133) Taxee withheld and paid on employee stock awards vested (1,437) (600) Issuance of subsidiary shares to non-controlling interests 7,796 - Divide | | | |
| Investing ActivitiesPurchase of property, plant and equipment(13,368)(24,143)Investment in joint revenue sharing equipment(34,810)(42,634)Investment in new business ventures | | | |
| Purchase of property, plant and equipment(13,368)(24,143)Investment in joint revenue sharing equipment(34,810)(42,634)Investment in new business ventures–(1,606)Acquisition of other intangible assets(8,696)(5,214)Net cash used in investing activities(56,874)(73,597)Financing Activities(56,874)(73,597)Financing Activities(50,667)(2,000)Reparment of bank indebtedness(50,667)(2,000)Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)–Settlement of restricted share units and options(916)(20,331)Common shares issued—stock optione sercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796–Credit facility amendment fees paid(1,909)––Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash(629(26,72)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | | | |
| Investment in joint revenue sharing equipment(34,810)(42,634)Investment in new business ventures—(1,606)Acquisition of other intangible assets(8,696)(5,214)Net cash used in investing activities(56,874)(73,597)Financing Activities—(56,874)(73,597)Increase in bank indebtedness65,000—Repayment of bank indebtedness(50,667)(2,000)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796—Dividends paid to non-controlling interests(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | | (13,368) | (24,143) |
| Investment in new business ventures—(1,606)Acquisition of other intangible assets(8,696)(5,214)Net cash used in investing activities(56,874)(73,597)Financing Activities——Increase in bank indebtedness(50,667)(2,000)Repayment of bank indebtedness(50,667)(2,000)Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796—Dividends paid to non-controlling interests(1,949)—Credit facility amendment fees paid(1,909)—Net cash used in financing activities(27,356)(267)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | | | |
| Acquisition of other intangible assets(8,696)(5,214)Net cash used in investing activities(56,874)(73,597)Financing Activities50,000Increase in bank indebtedness65,000Repayment of bank indebtedness(50,667)(2,000)Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796Dividends paid to non-controlling interests(1,909)Net cash used in financing activities(19,909)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Investment in new business ventures | _ | |
| Financing ActivitiesIncrease in bank indebtedness65,000Repayment of bank indebtedness(50,667)Repayment of bank indebtedness(50,667)Repurchase of common shares(71,479)Repurchase of common shares, IMAX China(6,084)Repurchase of common shares, IMAX China(6,084)Common shares issued—stock options exercised1,017Common shares issued—stock options exercised1,017Treasury stock repurchased for future settlement of restricted share units(5,249)Taxes withheld and paid on employee stock awards vested(1,437)Issuance of subsidiary shares to non-controlling interests7,796Dividends paid to non-controlling interests(6,934)Credit facility amendment fees paid(1,909)Net cash used in financing activities(70,862)Effects of exchange rate changes on cash629Cerease in cash and cash equivalents during year(17,135)Cash and cash equivalents, beginning of year158,725204,759 | Acquisition of other intangible assets | (8,696) | (5,214) |
| Financing ActivitiesIncrease in bank indebtedness65,000Repayment of bank indebtedness(50,667)Repayment of bank indebtedness(50,667)Repurchase of common shares(71,479)Repurchase of common shares, IMAX China(6,084)Repurchase of common shares, IMAX China(6,084)Settlement of restricted share units and options(916)Common shares issued—stock options exercised1,017Treasury stock repurchased for future settlement of restricted share units(5,249)Taxes withheld and paid on employee stock awards vested(1,437)Issuance of subsidiary shares to non-controlling interests7,796Dividends paid to non-controlling interests(6,934)Credit facility amendment fees paid(1,909)Net cash used in financing activities(70,862)Effects of exchange rate changes on cash629Cerease in cash and cash equivalents during year(17,135)Cash and cash equivalents, beginning of year158,725204,759 | Net cash used in investing activities | (56,874) | (73,597) |
| Increase in bank indebtedness65,000—Repayment of bank indebtedness(50,667)(2,000)Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796—Dividends paid to non-controlling interests(6,934)—Credit facility amendment fees paid(1,909)—Net cash used in financing activities(57,536)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Financing Activities | | ; |
| Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)—Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796—Dividends paid to non-controlling interests(6,934)—Credit facility amendment fees paid(1,909)—Net cash used in financing activities(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Increase in bank indebtedness | 65,000 | _ |
| Repurchase of common shares(71,479)(46,140)Repurchase of common shares, IMAX China(6,084)-Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Repayment of bank indebtedness | (50,667) | (2,000) |
| Settlement of restricted share units and options(916)(20,331)Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(20,7536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Repurchase of common shares | (71,479) | (46,140) |
| Common shares issued—stock options exercised1,01716,668Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Repurchase of common shares, IMAX China | (6,084) | _ |
| Treasury stock repurchased for future settlement of restricted share units(5,249)(5,133)Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Settlement of restricted share units and options | (916) | (20,331) |
| Taxes withheld and paid on employee stock awards vested(1,437)(600)Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Common shares issued—stock options exercised | 1,017 | 16,668 |
| Issuance of subsidiary shares to non-controlling interests7,796-Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Treasury stock repurchased for future settlement of restricted share units | (5,249) | (5,133) |
| Dividends paid to non-controlling interests(6,934)-Credit facility amendment fees paid(1,909)-Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Taxes withheld and paid on employee stock awards vested | (1,437) | (600) |
| Credit facility amendment fees paid(1,909)—Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Issuance of subsidiary shares to non-controlling interests | 7,796 | — |
| Net cash used in financing activities(70,862)(57,536)Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | | (6,934) | — |
| Effects of exchange rate changes on cash629(267)Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Credit facility amendment fees paid | (1,909) | |
| Decrease in cash and cash equivalents during year(17,135)(46,034)Cash and cash equivalents, beginning of year158,725204,759 | Net cash used in financing activities | (70,862) | (57,536) |
| Cash and cash equivalents, beginning of year158,725204,759 | Effects of exchange rate changes on cash | 629 | (267) |
| Cash and cash equivalents, beginning of year158,725204,759 | Decrease in cash and cash equivalents during year | (17,135) | (46,034) |
| Cash and cash equivalents, end of year \$141,590 \$158,725 | Cash and cash equivalents, beginning of year | | |
| | Cash and cash equivalents, end of year | \$ 141,590 | \$ 158,725 |

IMAX CORPORATION SELECTED FINANCIAL DATA In accordance with United States Generally Accepted Accounting Principles

(in thousands of U.S. dollars)

The Company has four primary reporting groups identified by nature of product sold or service provided: (1) Network Business, reporting variable revenue generated by box-office results and which includes the reportable segments of IMAX DMR and contingent rent from the JRSAs and IMAX systems-segments; (2) Theater Business, representing revenue generated by the sale and installation of theater systems and maintenance services, primarily related to the IMAX Systems and Theatre System Maintenance reportable segments, and also includes fixed hybrid revenue and upfront installation costs from the JRSA segment; (3) New Business, which includes content licensing and distribution fees associated with our content investments, virtual reality initiatives, IMAX Home Entertainment, and other business initiatives that are in the development and/or start-up phase, and (4) Other; which includes the film post-production and distribution segments and certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items.

| | Ended De | Three Months Ended December 31, | | Ended cember 31, |
|---|-----------|------------------------------------|-----------|---------------------|
| Revenue | 2018 | 2017 | 2018 | 2017 |
| Network Business | | | | |
| IMAX DMR | \$ 25,207 | \$ 31,717 | \$110,793 | \$108,853 |
| Joint revenue sharing arrangements - contingent rent | 16,452 | 20,741 | 73,371 | 70,444 |
| IMAX systems - contingent rent | | 1,317 | | 3,890 |
| | 41,659 | 53,775 | 184,164 | 183,187 |
| Theater Business | | | | |
| IMAX systems | | | | |
| Sales and sales-type leases | 37,887 | 31,675 | 88,432 | 79,853 |
| Ongoing fees and finance income | 3,242 | 2,650 | 12,224 | 10,494 |
| Joint revenue sharing arrangements – fixed fees | 5,885 | 5,582 | 9,706 | 10,118 |
| Theater system maintenance | 12,222 | 11,924 | 49,684 | 45,383 |
| Other theater | 2,651 | 3,696 | 8,358 | 9,145 |
| | 61,887 | 55,527 | 168,404 | 154,993 |
| New Business | 770 | 13,014 | 5,769 | 24,522 |
| Other | | , | | ,c _ |
| Film distribution and post-production | 3,806 | 1,803 | 12,962 | 13,172 |
| Other | 842 | 1,433 | 3,102 | 4,893 |
| | 4,648 | 3,236 | 16,064 | 18,065 |
| Fotal revenues | \$108,964 | \$125,552 | \$374,401 | \$380,767 |
| Gross margin | | | | |
| Network Business | | | | |
| IMAX DMR (1) | \$ 15,250 | \$ 19,211 | \$ 72,773 | \$ 71,789 |
| Joint revenue sharing arrangements – contingent rent ⁽¹⁾ | 9,415 | 14,066 | 48,856 | 47,337 |
| IMAX systems– contingent rent | _ | 1,317 | | 3,890 |
| | 24,665 | 34,594 | 121,629 | 123,016 |
| Theater Business | | | | |
| IMAX systems (1) | | | | |
| Sales and sales-type leases | \$ 19,338 | \$ 19,449 | \$ 47,986 | \$ 47,639 |
| Ongoing fees and finance income | 3,194 | 2,513 | 12,033 | 10,095 |
| Joint revenue sharing arrangements – fixed fees (1) | 1,206 | 1,462 | 1,982 | 2,349 |
| Theater system maintenance | 4,702 | 4,969 | 21,991 | 18,275 |
| Other theater | 707 | 883 | 1,806 | 1,965 |
| | 29,147 | 29,276 | 85,798 | 80,323 |
| New Business | (489) | (2,744) | (350) | (16,176 |
| Dther | | | | |
| Film distribution and post-production (1) | 1.443 | (744) | 1,763 | (1,006 |
| Other | (124) | (234) | (911) | (911 |
| | 1,319 | (978) | 852 | (1,917 |
| Fotal segment margin | \$ 54,642 | \$ 60,148 | \$207,929 | \$185,246 |

(1) IMAX DMR segment margins include marketing costs of \$2.8 million and \$16.5 million for the three months and year ended, respectively (2017 —\$5.6 million and \$15.4 million, respectively). Joint revenue sharing arrangements segment margins include advertising, marketing and commission costs of \$1.4 million and \$3.6 million for the three months and year ended, respectively (2017—\$2.0 million and \$4.5 million, respectively). IMAX system segment margins include marketing and commission costs of \$0.9 million and \$2.9 million for the three months and year ended, respectively (2017—\$1.3 million and \$3.5 million). Film distribution and post production segment margins include marketing expense of \$0.2 million and \$2.2 million for the three months and year ended (2017—an expense of \$nil and recovery of \$0.7 million, respectively).

IMAX CORPORATION OTHER INFORMATION (in thousands of U.S. dollars)

Non-GAAP Financial Measures:

In this release, the Company presents adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders per diluted share, EBITDA and adjusted EBITDA per Credit Facility as supplemental measures of performance of the Company, which are not recognized under U.S. GAAP. The Company presents adjusted net income and adjusted net income per diluted share because it believes that they are important supplemental measures of its comparable controllable operating performance and it wants to ensure that its investors fully understand the impact of its stock-based compensation (net of any related tax impact) and non-recurring charges on net income. In addition, the Company presents adjusted net income attributable to common shareholders per diluted share because it believes that they are important supplemental measures of its comparable financial results and could potentially distort the analysis of trends in business performance and it wants to ensure that its investors fully understand the impact of of any related tax impact) and non-recurring charges in determining net income attributable to common shareholders. Management uses these measures to review operating performance on a comparable basis from period to period. However, these non-GAAP measures may not be comparable to similarly titled amounts reported by other companies. Adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders are adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders. Management uses these measures to review operating performance on a comparable basis from period to period. However, these non-GAAP measures may not be comparable to similarly titled amounts reported by other companies. Adjusted net income attributable to common shareholders and adjusted net incom

The Company is required to maintain a minimum level of "EBITDA", as such term is defined in the Company's credit agreement (and which is referred to herein as "Adjusted EBITDA per Credit Facility" or "Adjusted EBITDA per Credit Facility excluding *Marvel's Inhumans*", as the credit agreement includes additional adjustments beyond interest, taxes, depreciation and amortization). EBITDA and Adjusted EBITDA per Credit Facility (each as defined below) should not be construed as substitutes for net income or as better measures of liquidity as determined in accordance with U.S. GAAP. The Company believes that EBTDA and Adjusted EBITDA per Credit Facility excluding *Marvel's Inhumans* are relevant and useful information widely used by analysts, investors and other interested parties in the Company's industry.

| (In thousands of U.S. Dollars) | | rter Ended <u>aber 31, 2018</u> | | ear Ended ber 31, 2018 (1) | | ear Ended nber 31, 2017 |
|---|----|------------------------------------|----|-------------------------------|----|----------------------------|
| Net income | \$ | 3,771 | \$ | 33,595 | \$ | 12,518 |
| Add (subtract): | Ŷ | 5,772 | Ŷ | 00,000 | Ŷ | 12,010 |
| Provision for income taxes | | (22) | | 9,518 | | 16,790 |
| Interest expense, net of interest income | | (110) | | 1,072 | | 915 |
| Depreciation and amortization, | | | | | | |
| including film asset amortization (1) | | 15,453 | | 57,437 | | 66,245 |
| EBITDA | | 19,092 | | 101,622 | | 96,468 |
| Stock and other non-cash compensation | | 5,483 | | 23,723 | | 23,718 |
| Write-downs, net of recoveries including asset impairments and receivable provisions ⁽¹⁾ | | 2,797 | | 5,338 | | 24,015 |
| Exit costs, restructuring charges and | | 2,707 | | 5,550 | | 21,010 |
| associated impairments | | 8,384 | | 9,542 | | 16,174 |
| Legal arbitration award | | 4,237 | | 11,737 | | |
| Executive transition costs | | 2,994 | | 2,994 | | |
| (Gain) loss from equity accounted | | | | , | | |
| investments | | (15) | | 492 | | 703 |
| Adjusted EBITDA before | | | | | | |
| non-controlling interests | | 42,972 | | 155,448 | | 161,078 |
| Adjusted EBITDA attributable to non-controlling interests ⁽²⁾ | | (6,593) | | (22,220) | | (22,927) |
| Adjusted EBITDA per Credit Facility | \$ | 36,379 | \$ | 133,228 | \$ | 138,151* |
| Adjusted EBITDA per Credit Facility, excluding impact from "Marvel's Inhumans" | \$ | 36,379 | \$ | 133,228 | \$ | 126,158* |
| Adjusted revenues attributable to | ÷ | | ¥ | 100,20 | + | |
| common shareholders | \$ | 97,573 | \$ | 336,723 | \$ | 340,460 |
| Adjusted EBITDA margin, excluding impact from "Marvel's Inhumans" | | 37.3% | | 39.6% | | 37.1% |

* Adjusted EBITDA per Credit Facility of \$138.2 million includes the impact of the Company's investment in "Marvel's Inhumans", which resulted in a \$13.0 million loss. However, as permitted by the Credit Facility, this loss was offset by addbacks of \$13.3 million and \$11.7 million for amortization and impairment charges, respectively, relating to the investment, the net effect of which was to increase Adjusted EBITDA per Credit Facility by \$12.0 million. This investment represents the Company's first foray into a commercial television property, and therefore the Adjusted EBITDA per Credit Facility metric presented above may not be reflective of the Company's typical operational activity. Further, the Company does not yet know whether it will make similar investments in the future. As a result, the Company is also presenting Adjusted EBITDA per Credit Facility excluding the impact of "Marvel's Inhumans" to better facilitate comparisons to prior and future periods.

(1) Senior Secured Net Leverage Ratio calculated using twelve months ended Adjusted EBITDA per Credit Facility.

(2) The Adjusted EBITDA per Credit Facility calculation includes the reduction in Adjusted EBITDA per Credit Facility from the Company's non-controlling interests.

| (3) | Quarter Ended December 31, 2018 | Year Ended December 31, 2018 | Year Ended December 31, 2017 |
|--|------------------------------------|---------------------------------|---------------------------------|
| Total revenues | \$108,9 | 64 \$374,4 | 01 \$380,767 |
| Greater China revenues | \$35,553 | \$117,520 | \$126,474 |
| Non-controlling interest ownership percentage(4) | 32.04% | 32.06% | 31.87% |
| Deduction for non-controlling interest share of revenues | (11,3 | 91) (37,6 | 78) (40,307) |
| Adjusted revenues attributable to common shareholders | <u>\$ 97,5</u> | <u>73</u> \$ <u>336,7</u> | <u>23</u> <u>\$ 340,460</u> |

(4) Weighted average ownership percentage for change in non-controlling interest share

Return on Invested Capital:

| | 2018 | 2017 |
|---|-----------|-----------|
| Income from operations | \$ 45,176 | \$ 31,444 |
| Provision for income taxes | (9,518) | (16,790) |
| EBIAT Return | \$ 35,658 | \$ 14,654 |
| Total shareholders' equity | \$592,918 | \$602,257 |
| Total bank indebtedness | 37,753 | 25,357 |
| Less: Goodwill | 39,027 | 39,027 |
| Less: Other intangible assets | 34,095 | 31,211 |
| Total Invested Capital | \$557,549 | \$557,376 |
| Return on Invested Capital (Non-GAAP measure) | 6.4% | 2.6%* |

* Return on Invested Capital (ROIC) is not defined under U.S. generally accepted accounting principles. Therefore, ROIC should not be considered a substitute for other measures prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The Company defines ROIC as earnings before interest after taxes (before non-controlling interests) divided by total invested capital (total equity plus total debt less goodwill and other intangible assets). The Company believes ROIC is meaningful to investors as it focuses on shareholder value creation.

IMAX CORPORATION OTHER INFORMATION

(in thousands of U.S. dollars)

Adjusted Net Income and Adjusted Diluted Per Share Calculations – Quarter Ended December 31, 2018 vs. 2017:

The Company reported net income of \$3.8 million or \$0.06 per basic and diluted share for the quarter ended December 31, 2018 as compared to net income of \$8.7 million or \$0.13 per basic and diluted share for the quarter ended December 31, 2017.

Net income for the quarter ended December 31, 2018 includes a \$5.0 million charge or \$0.08 per diluted share (2017 — \$4.9 million or \$0.08 per diluted share) for stock-based compensation, a \$8.4 million charge, or \$0.13 per diluted share for exit costs, restructuring charges and associated impairments (2017—\$2.5 million or \$0.04 per diluted share), a \$4.2 million, or \$0.07 per diluted share, for a legal arbitration award related to one of the Company's litigation matters from 2006 (2017- \$nil) and a \$3.0 million, or \$0.05 per diluted share for executive transition costs (2017 — \$nil). In 2017, the Company also recognized a \$9.3 million, or \$0.14 per diluted share, non-recurring tax charge as the Company re-measured its deferred tax assets and liabilities as at the date of enactment of the amended Tax Cut and Jobs Act.

Adjusted net income, which consists of net income excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the legal arbitration award, executive transition costs, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was \$19.8 million, or \$0.32 per diluted share, for the quarter ended December 31, 2018 as compared to adjusted net income of \$25.7 million or \$0.40 per diluted share for the quarter ended December 31, 2017.

The Company reported net income attributable to common shareholders of \$1.7 million, or \$0.03 per basic and diluted share for the year ended December 31, 2018 (2017 — \$4.8 million, or \$0.08 per basic and diluted share).

Adjusted net income attributable to common shareholders, which consists of net income attributable to common shareholders excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the legal arbitration award, executive transition costs, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was \$16.4 million, or \$0.26 per diluted share, for the quarter ended December 31, 2018 as compared to adjusted net income attributable to common shareholders of \$21.8 million or \$0.34 per diluted share for the quarter ended December 31, 2017.

A reconciliation of net income and net income attributable to common shareholders, the most directly comparable U.S. GAAP measure, to adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share is presented in the table below:

| | Quarter Ended December 31, | | | |
|---|----------------------------|-------------|------------|-------------|
| | 20 | - | 20 | |
| Descrited and income | Net Income | Diluted EPS | Net Income | Diluted EPS |
| Reported net income | \$ 3,771 | \$ 0.06 | \$ 8,698 | \$ 0.13 |
| Adjustments: | | | | |
| Stock-based compensation | 5,046 | 0.08 | 4,857 | 0.08 |
| Exit costs, restructuring charges and associated impairments | 8,384 | 0.13 | 2,479 | 0.04 |
| Legal arbitration award | 4,237 | 0.07 | — | — |
| Executive transition costs | 2,994 | 0.05 | — | — |
| Tax impact on items listed above | (4,586) | (0.07) | 360 | 0.01 |
| Impact of enactment of U.S. Tax Act | | | 9,323 | 0.14 |
| Adjusted net income | 19,846 | 0.32 | 25,717 | 0.40 |
| Net income attributable to non-controlling interests (1) | (2,077) | (0.04) | (3,867) | (0.06) |
| Stock-based compensation (net of tax of less than \$0.1 | | | | |
| million and less than \$0.1 million, respectively) ⁽¹⁾ | (115) | — | (76) | — |
| Exit costs, restructuring charges and associated impairments | | | | |
| (net of tax of \$0.4 million and \$nil, respectively) (1) | (1,262) | (0.02) | (2) | |
| Adjusted net income attributable to common shareholders | \$ 16,392 | \$ 0.26 | \$ 21,774 | \$ 0.34 |
| Weighted average diluted shares outstanding | | 62,127 | | 64,790 |

(1) Reflects amounts attributable to non-controlling interests.

Adjusted Net Income and Adjusted Diluted Per Share Calculations – Year Ended December 31, 2018 vs. 2017:

The Company reported net income of \$33.6 million or \$0.53 per basic and diluted share for the year ended December 31, 2018 as compared to net income of \$12.5 million and \$0.19 per basic and diluted share, for the year ended December 31, 2017.

Net income for the year ended December 31, 2018 includes a \$22.2 million charge or \$0.35 per diluted share (2017 — \$22.7 million or \$0.35 per diluted share) for stock-based compensation, a \$9.5 million charge or \$0.15 per diluted share for exit costs, restructuring charges and associated impairments (2017—\$16.2 million or \$0.25 per diluted share), a \$11.7 million, or \$0.19 per diluted share, for a legal arbitration award related to one of the Company's litigation matters from 2006 (2017 — \$nil) and a \$3.0 million, or \$0.05 per diluted share for executive transition costs (2017 — \$nil). In 2017, the Company also recognized a \$9.3 million, or \$0.14 per diluted share, non-recurring tax charge as the Company re-measured its deferred tax assets and liabilities as of the date of enactment of the recently passed Tax Act.

Adjusted net income, which consists of net income excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the legal arbitration award, executive transition costs, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was \$70.2 million, or \$1.11 per diluted share, for the year ended December 31, 2018 as compared to adjusted net income of \$51.5 million or \$0.79 per diluted share for the year ended December 31, 2017.

The Company reported net income attributable to common shareholders of \$22.8 million, or \$0.36 per basic and diluted share for the year ended December 31, 2018 (2017 — \$2.3 million, or \$0.04 per basic share and diluted share).

Adjusted net income attributable to common shareholders, which consists of net income attributable to common shareholders excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the legal arbitration award, executive transition costs, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was \$57.8 million or \$0.91 per diluted share for the year ended December 31, 2018 as compared to adjusted net income attributable to common shareholders of \$40.5 million or \$0.62 per diluted share for the year ended December 31, 2017.

A reconciliation of net income and net income attributable to common shareholders, the most directly comparable U.S. GAAP measure, to adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share is presented in the table below:

| | Year Ended December 31, | | | |
|---|-------------------------|-------------|------------|-------------|
| | | 18 | | 17 |
| | Net Income | Diluted EPS | Net Income | Diluted EPS |
| Reported net income | \$33,595 | \$0.53 | \$12,518 | \$0.19 |
| Adjustments: | | | | |
| Stock-based compensation | 22,211 | 0.35 | 22,653 | 0.35 |
| Exit costs, restructuring charges and associated impairments | 9,542 | 0.15 | 16,174 | 0.25 |
| Legal arbitration award | 11,737 | 0.19 | | |
| Executive transition costs | 2,994 | 0.05 | | — |
| Tax impact on items listed above | (9,873) | (0.16) | (9,218) | (0.14) |
| Impact of enactment of U.S. Tax Act | — | — | 9,323 | 0.14 |
| Adjusted net income | 70,206 | 1.11 | 51,450 | 0.79 |
| Net income attributable to non-controlling interests (1) | (10,751) | (0.17) | (10,174) | (0.16) |
| Stock-based compensation (net of tax of \$0.1 million, and | | | | |
| \$0.2 million, respectively) (1) | (394) | (0.01) | (620) | (0.01) |
| Exit costs, restructuring charges and associated impairments | | | | |
| (net of tax of \$0.4 million and \$0.1 million, respectively) | | | | |
| (1) | (1,262) | (0.02) | (181) | |
| Adjusted net income attributable to common shareholders | \$ 57,799 | \$ 0.91 | \$ 40,475 | \$ 0.62 |
| Weighted average diluted shares outstanding | | 63,207 | | 65,540 |
| | | | | |

(1) Reflects amounts attributable to non-controlling interests.

Free Cash Flow:

Free cash flow is defined as cash provided by operating activities minus cash used in investing activities (from the consolidated statements of cash flows). Cash provided by operating activities consist of net income, plus depreciation and amortization, plus the change in deferred income taxes, plus other non-cash items, plus changes in working capital, less investment in film assets, plus other changes in operating assets and liabilities. Cash used in investing activities includes capital expenditures, acquisitions and other cash used in investing activities. Management views free cash flow, a non-GAAP measure, as a measure of the Company's after-tax cash flow available to reduce debt, add to cash balances, and fund other financing activities. A reconciliation of cash provided by operating activities to free cash flow is presented in the table below:

| (In thousands of U.S. Dollars) | 3 ma | For the onths ended nber 31, 2018 | For the months ended ember 31, 2018 |
|---|------|---|---|
| Net cash provided by operating activities | \$ | 41,902 | \$ 109,972 |
| Net cash used in investing activities | | (23,599) | (56,874) |
| Free cash flow | \$ | 18,303 | \$ 53,098 |